

ARTICLE

Received 3 Oct 2012 | Accepted 3 Jan 2013 | Published 5 Feb 2013

DOI: 10.1038/ncomms2445

# Ephrin-A5/EphA4 signalling controls specific afferent targeting to cochlear hair cells

Jean Defourny<sup>1</sup>, Anne-Lise Poirrier<sup>1,2,†</sup>, François Lallemand<sup>3</sup>, Susana Mateo Sánchez<sup>1</sup>, Jakob Neef<sup>4</sup>, Pierre Vanderhaeghen<sup>5</sup>, Eduardo Soriano<sup>6</sup>, Christiane Peuckert<sup>7</sup>, Klas Kullander<sup>7</sup>, Bernd Fritsch<sup>8</sup>, Laurent Nguyen<sup>1</sup>, Gustave Moonen<sup>1,9</sup>, Tobias Moser<sup>4</sup> & Brigitte Malgrange<sup>1</sup>

Hearing requires an optimal afferent innervation of sensory hair cells by spiral ganglion neurons in the cochlea. Here we report that complementary expression of ephrin-A5 in hair cells and EphA4 receptor among spiral ganglion neuron populations controls the targeting of type I and type II afferent fibres to inner and outer hair cells, respectively. In the absence of ephrin-A5 or EphA4 forward signalling, a subset of type I projections aberrantly overshoot the inner hair cell layer and invade the outer hair cell area. Lack of type I afferent synapses impairs neurotransmission from inner hair cells to the auditory nerve. By contrast, radial shift of type I projections coincides with a gain of presynaptic ribbons that could enhance the afferent signalling from outer hair cells. Ephexin-1, cofilin and myosin light chain kinase act downstream of EphA4 to induce type I spiral ganglion neuron growth cone collapse. Our findings constitute the first identification of an Eph/ephrin-mediated mutual repulsion mechanism responsible for specific sorting of auditory projections in the cochlea.

<sup>1</sup>GIGA-Neurosciences, Developmental Neurobiology Unit, University of Liège, C.H.U. B36, Liège B-4000, Belgium. <sup>2</sup>ENT department, CHU de Liège, Liège, B-4000, Belgium. <sup>3</sup>Unit of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Scheeles väg 1-A1-plan2, Stockholm S-17177, Sweden. <sup>4</sup>InnerEarLab, Department of Otolaryngology and Sensory Research Center 889, University of Göttingen Medical Center, Robert Kochstr. 40, D-37075 Göttingen, Germany. <sup>5</sup>Institute of Interdisciplinary Research on Human and Molecular Biology (IRIBHM), Université Libre de Bruxelles (ULB), Route de Lennik 808, Brussels B-1070, Belgium. <sup>6</sup>Developmental Neurobiology and Regeneration Unit, Institut de Recerca Biomèdica (IRB) and University of Barcelona, Parc Científic de Barcelona, Josep Samitier 1-5, Barcelona E-08028, Spain. <sup>7</sup>Department of Neuroscience, Uppsala University, Box 593, Uppsala S-75124, Sweden. <sup>8</sup>Department of Biology, College of Liberal Arts and Sciences, University of Iowa, 143, Biology Building, Iowa City, Iowa 52242-1324, USA. <sup>9</sup>Department of Neurology, C.H.U. Sart Tilman, B35, Liège B-4000, Belgium. † Present address: Royal National Throat Nose Ear Hospital, University College London, London, WC1X8DA, UK. Correspondence and requests for materials should be addressed to B.M. (email: bmalgrange@ulg.ac.be).

Hearing requires an optimal innervation of sensory hair cells (HCs), which transduce the acoustic signal. HCs receive two different types of innervation: afferent innervation from spiral ganglion (SG) neurons (SGNs)<sup>1,2</sup> and efferent innervation from the superior olivary complex<sup>2-4</sup>. The primary afferent innervation includes two functionally distinct neuronal populations conveying sound information from the cochlea to the central nervous system. In the adult sensory epithelium, the organ of Corti (OC), each inner HC (IHC) connects over 10 type I SGNs (about 90–95% of the neuronal population) and represents the principal encoder of the auditory signal. By contrast, outer HCs (OHCs) display an ‘en passant’ innervation by type II SGNs (approximately 5–10% of the total neuronal population) (Fig. 7a). The function of these type II connections is still unclear, but they may monitor and regulate OHC gain.

In rodents, the development of cochlear innervation starts at early embryonic stages and is completed by the end of the first postnatal week. This process is divided into three main phases: (a) neurite growth and extension of type I and type II afferents to HCs (before birth), (b) axon refinement and HC innervation (postnatal day 0; P0–P3) and (c) neurite retraction and synaptic pruning (P3–P6)<sup>5</sup>. Axon guidance depends on the motility of navigating growth cones that respond to nondiffusible extracellular matrix molecules, transmembrane proteins expressed in neighbouring cells and diffusible chemotropic agents released by the target epithelium. These cues successively exert either repulsive or attractive influences on outgrowing axons and finally give rise to accurate targeting of auditory projections<sup>6</sup>. Importantly, although the mechanisms required for axon guidance to the OC become better characterized, the molecules underlying the specific refinement of type I and type II afferents to respective HCs remain elusive.

Among gene families that have been shown to regulate neurite guidance, ephrins and their Eph receptors are good candidates for patterning auditory neural connectivity. Ephrin-As and EphA receptors are often expressed in complementary gradients in target cells and projecting neurons, respectively<sup>7,8</sup>. Particularly, both *in vitro* and *in vivo* findings have shown that ephrin-A5 induces growth cone collapse and axon repulsion upon binding to EphA receptors, avoiding formation and stabilization of axon branching and arborization at inaccurate locations<sup>9</sup>.

This large Eph family has been classified into two subclasses, EphA and EphB, according to their affinity for either glycosylphosphatidylinositol-anchored ephrin-A or transmembrane ephrin-B ligands<sup>10</sup>. Immunohistochemical studies previously suggested alternating expression patterns of ephrins and Eph receptors in the developing inner ear<sup>11,12</sup>.

On the basis of their well-described role in topographic mapping in several parts of central and peripheral nervous systems, we suggested that ephrin/Eph genes control the proper patterning of radial SGN projections in the cochlea. Here we found that ephrin-A5 and EphA4, expressed, respectively, in OHCs and type I SGNs, display complementary expression profiles at perinatal stages. In the absence of *ephrin-A5* or EphA4 forward signalling, a subset of type I projections aberrantly overshoot the IHC layer and invade the OHC area, thereby suggesting an Eph/ephrin-mediated mutual repulsion mechanism responsible for specific afferent targeting to cochlear HCs.


## Results

**Differential expressions of ephrin-A5 and EphA4.** Among the ephrin ligand family, ephrin-A5 is most commonly involved in topographic map specification through graded expression in the target region<sup>9,13,14</sup>. We therefore examined the ephrin-A5

expression in HCs during the formation of radial afferent projections in the cochlea. Ephrin-A5 mRNA and protein are specifically detected in OHCs between E18 and P4 (Fig. 1j–n and Supplementary Fig. S1a–c), a period characterized by neurite refinement and HC innervation<sup>7</sup>. Surprisingly, *ephrin-A5* is also expressed in a subset of type I SGNs (Fig. 1j,o–t and Supplementary Fig. 1d–f). This *ephrin-A5*<sup>+</sup> SGN subpopulation reaches a peak at P0 (Fig. 1u and Supplementary Fig. 1d,e). During the same time window, EphA4 is widely expressed in SG cells, especially in  $\beta$ III-tubulin<sup>+</sup> SGNs (Fig. 1a,c,d,i and Supplementary Fig. S1g–l). However, both transcript and EphA4<sup>EGFP</sup> remain preferentially confined to type I SGNs. Indeed, peripherin<sup>+</sup> type II SGNs<sup>15</sup> are negative for EphA4 expression (Fig. 1a,b,d–f). Among Eph receptors (that is, EphAs and EphBs (ref. 16)) that interact with ephrin-A5, EphA4 is the only one exhibiting such striking expression pattern in the SG, distinguishing type I from type II SGNs. EphA4<sup>EGFP</sup> is also detectable in fibres that are specifically retained to IHCs at P2 (Fig. 1g,h). Taken together, these results suggest that ephrin-A5 and EphA4 display matching complementary expression profiles at perinatal stages (Fig. 1v), consistent with a role in specific afferent targeting to HCs in the cochlea.

**Mistargeting of afferent fibres to HCs in ephrin-A5<sup>-/-</sup> cochlea.** To assess the role of ephrin-A5 in contributing to proper cochlear innervation, we performed neurofilament H (NF-H) and peripherin co-immunostaining on whole-mount post-hearing-onset (P14) cochleae<sup>17</sup> from wild type (WT) and *ephrin-A5*<sup>-/-</sup> littermates<sup>9</sup>. Compared with the WT phenotype, a radial shift in innervation pattern from IHCs to OHCs is observed in *ephrin-A5*<sup>-/-</sup> mice (Fig. 2a–f). In WT mice, most axons contacting OHCs belong to type II SGNs (NF-H<sup>+</sup>/peripherin<sup>+</sup>) (Fig. 2g,h), as previously described<sup>15</sup>. By contrast, a large majority of fibres targeting the OHCs in *ephrin-A5*<sup>-/-</sup> animals correspond to peripherin<sup>-</sup> ectopic innervation (Fig. 2i,j). Quantitative analysis revealed that the number of NF-H<sup>+</sup>/peripherin<sup>-</sup> projections to the OHC region is significantly increased in *ephrin-A5*<sup>-/-</sup> P14 littermates (Fig. 2u). This suggests that loss of *ephrin-A5* expression allowed a subset of type I SGNs to target the OHC layer instead of wiring with IHCs. In addition, although type II SGNs classically exhibit extensive arborization and innervate several OHCs in WT (Fig. 2h), they send shortened projections in *ephrin-A5*<sup>-/-</sup> mice (Fig. 2j). The percentage of type II fibres whose length is < or > to 200  $\mu$ m after entering the OC is, respectively, increased and decreased in *ephrin-A5*<sup>-/-</sup> cochleae as compared with WT (Fig. 2v). This defect probably arises from axon competition induced by massive ectopic projections randomly invading the OHC area. Importantly, the number of IHC and OHC rows (1 and 3, respectively) and the number of total SGNs and peripherin<sup>+</sup> type II SGNs remain unchanged in the absence of *ephrin-A5* (Supplementary Figs S2 and S3a–f).

Sensory synapses of the auditory system must faithfully encode a wide dynamic range of graded signals, and must be capable of sustained transmitter release over long periods of time. These properties require specialized structures called synaptic ribbons. These ribbons are electron-dense presynaptic specializations that tether synaptic vesicles, allowing rapid exocytosis and fast synaptic transmission<sup>18,19</sup>. The major structural component of synaptic ribbons identified so far is RIBEYE, a protein aggregate formed by a unique and ribbon-specific A domain, and a dimeric B domain identical to CtBP2, a transcriptional repressor protein<sup>20</sup>. In the mammalian cochlea, outside of the extreme apex, >95% of cochlear nerve fibres are unbranched, contacting a single IHC via a single terminal swelling, with a single active zone at which a single presynaptic ribbon is tethered to the IHC



**Figure 1 | Complementary expression patterns of ephrin-A5 and EphA4 in HCs and SGNs.** (a,b) Confocal images of SG cells on transversal section of PO cochlea processed for ISH with *EphA4* probe (a) and for peripherin immunostaining (b). Note that peripherin<sup>+</sup> type II SGNs (arrowheads in b) expressed lower levels of *EphA4* as compared with peripherin<sup>-</sup> cells. (c-f) Triple immunolabeling on transversal section of SG from PO *EphA4*<sup>+/EGFP</sup> mouse showing that *EphA4*<sup>EGFP</sup> is expressed in SGNs (yellow arrowheads in c,d,f) but absent from peripherin<sup>+</sup> type II SGNs (white arrowhead in d-f). (g,h) Immunolabeling of whole-mount P2 *EphA4*<sup>+/EGFP</sup> cochlea showing the presence of EGFP (arrowheads in g) in NF-H<sup>+</sup> fibres (arrowheads in h) retained at IHCs. ISH on transversal sections of P2 (i) and P0 (j) cochleae showing the expression of *EphA4* (i) and *ephrin-A5* (j) along the basal-to-apical axis of the cochlea. (k-n) ISH (k) and immunolabeling (l-n) on transversal section of a newborn mouse OC showing a prominent expression of *ephrin-A5* mRNA and protein in OHCs compared with IHC. (o-t) Confocal images of SG on transversal section of PO cochlea processed for ISH with *ephrin-A5* probe (o,q,s) and for  $\beta$ III-tubulin (p,r) or peripherin immunostaining (t). Note that *ephrin-A5* is expressed in a subset of SGNs (blue arrowhead in q, yellow arrowhead in r) but is absent from peripherin<sup>+</sup> type II SGNs (blue arrowheads in s, yellow arrowheads in t). (u) Quantification of *ephrin-A5*<sup>+</sup> SGNs across developmental stages. This *ephrin-A5*<sup>+</sup> SGN subpopulation reaches a peak at P0. Data are presented as mean  $\pm$  s.e.m. (v) Schematic representation of ephrin-A5 (blue)/EphA4 (green) complementary expressions in HCs and SGNs in the perinatal cochlea. Note that ephrin-A5 expression likely overlaps EphA4 in a subset of type I SGNs. Scale bars in (a) represents 10  $\mu$ m in (a,b), in (c), (g) and (k) 5  $\mu$ m in (c-f,q-t), (g,h) and (k-n) respectively, in (i) and (o) 25  $\mu$ m in (i,j) and (o,p) respectively.


membrane<sup>21</sup>. Thus, ribbon quantifications provide an accurate metric of the IHC afferent innervation<sup>22</sup>. It has to be pointed out that CtBP2<sup>+</sup> ribbons are not systematically coupled to NF-H<sup>+</sup> staining, because neurofilaments do not fill terminal axon swellings<sup>22</sup>. Consistent with the finding that some type I SGNs aberrantly project to the OHC region in *ephrin-A5*<sup>-/-</sup> mice, mean counts revealed a significant decrease of presynaptic active zones per IHC in *ephrin-A5*<sup>-/-</sup> compared with WT mice (Fig. 2k-n,s). We then wondered whether the lack of IHC afferent synapses in *ephrin-A5*<sup>-/-</sup> cochlea coincides with a gain of OHC synaptic ribbons. Ribbon counts revealed a significant increase of presynaptic active zones per row of OHCs in *ephrin-A5*<sup>-/-</sup> compared with WT mice (Fig. 2o-r,t). Combination of both results suggests that, in *ephrin-A5*<sup>-/-</sup> mice, the radial shift of type I projections from IHC to OHC layers is accompanied by a similar radial displacement of presynaptic active zones.

**Ephrin-A5/EphA4 is required for SGN projection sorting.**

When present in target cells, ephrin-A5 induces axon growth cone repulsion through activation of EphA receptors, avoiding propagation of ectopic projections in the region of expression<sup>9,23</sup>. To further understand the mechanism of axonal refinement in the OC occurring between P0 and P3, we considered using whole-mount cochleae from 2-day-old WT and *ephrin-A5*<sup>-/-</sup> mice

(Fig. 3a). At this stage, growing type I projections that have reached the first row of OHCs are progressively redirected to the basolateral region of IHCs<sup>5</sup>. In that respect, we observed that, in WT animals, most of the growing axons are stopped just beneath the first row of OHCs (Fig. 3b,d). By contrast, almost no refining fibres are distinguishable in the absence of *ephrin-A5*. A huge amount of neurites, instead of being repulsed by ephrin-A5<sup>+</sup> OHCs, abnormally overshoot the IHC layer and give rise to an aberrant OHC projection pattern (Fig. 3c,e). The proportion of fibres targeting the OHC layer is significantly higher in *ephrin-A5*<sup>-/-</sup> compared with WT animals (Fig. 3l).

To ascertain the requirement of ephrin-A5 in specific SGN afferent targeting to HCs, we used an organotypic assay, in which explants of OC and SG (devoid of efferent fibres from the brainstem) were isolated from E18 cochleae and cultured in order to examine the effect of acute ephrin-A5 signalling inhibition *in vitro*. To avoid any disruption with findings suggesting an EphA4-mediated axon guidance to the OC through binding to ephrin-B2 and -B3 (refs 24,25), we preferred to treat with soluble EphA7-Fc known to have a high affinity for ephrin-A5<sup>10</sup> rather than with EphA4-Fc. Tissues were maintained for 4 days in culture to analyse the processes of selective neurite refinement and HC innervation (Fig. 3a). In the control condition (IgG-Fc), the majority of growing axons are ending at the IHC level (Fig. 3h,j). By contrast, when blocking ephrin-A5-binding sites,




**Figure 2 | Radial shift in afferent HC innervation pattern in *ephrin-A5*<sup>-/-</sup> cochlea.** (a-f) NF-H immunolabeling alone (a,b) or in combination with myosin-VII (c-f) of whole-mount cochleae from post-hearing-onset WT (a,c,d) and *ephrin-A5*<sup>-/-</sup> (b,e,f) mice. Loss of *ephrin-A5* induces a radial shift in innervation pattern from the IHC to the OHC layers. The yellow dotted curve delimits the area of projections to OHCs. (g-j) Double immunolabeling for NF-H (g,i) and peripherin (h,j) on whole-mount cochleae from WT and *ephrin-A5*<sup>-/-</sup> mice. (g,h) In WT mice, almost all projections to OHCs are identified as type II fibres (NF-H<sup>+</sup>/peripherin<sup>+</sup>) and exhibit extensive arborization (yellow arrowheads). (i,j) In *ephrin-A5*<sup>-/-</sup> mice, the OHC innervation is more abundant and largely attributable to ectopic NF-H<sup>+</sup>/peripherin<sup>-</sup> projections. In addition, type II afferents (peripherin<sup>+</sup>) show incomplete innervation (yellow arrowheads) compared with WT. Yellow brackets indicate the OHC area. (k-n) Double NF-H—CtBP2/RIBEYE immunolabeling focused on IHCs from WT (k,l) and *ephrin-A5*<sup>-/-</sup> (m,n) mice. (o-r) Triple NF-H—parvalbumin—CtBP2/RIBEYE immunolabeling focused on OHCs from WT (o,p) and *ephrin-A5*<sup>-/-</sup> (q,r) mice. (s) The number of synaptic ribbons per IHC is significantly reduced in *ephrin-A5*<sup>-/-</sup> compared with WT mice ( $n = 3$  animals for both genotypes;  $**P < 0.01$ ). (t) The number of synaptic ribbons per row of OHCs is significantly increased in *ephrin-A5*<sup>-/-</sup> compared with WT mice ( $n = 3$  animals for both genotypes;  $**P < 0.01$ ). (u) The number of NF-H<sup>+</sup>/peripherin<sup>-</sup> fibres targeting the OHC layer is significantly increased in *ephrin-A5*<sup>-/-</sup> compared with WT mice ( $n = 3$  animals for both genotypes;  $***P < 0.001$ ). (v) The percentage of type II fibres of which length is  $< 200 \mu\text{m}$  after entering the OC is, respectively, significantly increased and decreased compared with WT ( $n = 3$  animals for both genotypes;  $**P < 0.01$ ). Statistical significance was determined using Student's *t*-test. Data are presented as mean  $\pm$  s.e.m. Scale bars in (a) represent  $50 \mu\text{m}$  in (a,b) and  $10 \mu\text{m}$  in (c-f), in (g)  $10 \mu\text{m}$  in (g-j), in (l)  $5 \mu\text{m}$  in (k-r), respectively.

most fibres extend radially to the OHC area (Fig. 3i,k). The proportion of afferent fibres targeting the OHC layer is significantly higher in *EphA7*-Fc compared with the control condition (Fig. 3n) without affecting neuron survival (Supplementary Fig. S3m,n,r). Both control and *EphA7*-Fc culture conditions seem to faithfully reproduce the stage of neurite refinement to HCs observed at P2 in WT and *ephrin-A5*<sup>-/-</sup> mice, respectively. These results confirm the involvement of *ephrin-A5* in specific afferent targeting to HCs in the cochlea. In support of this finding, a neuronal tracing experiment revealed that *ephrin-A5*<sup>-/-</sup> mice do not display any radial shift in efferent innervation pattern from IHCs to OHCs compared with WT animals (Supplementary Fig. S4). Altogether, these results indicate that mistargeting of afferent fibres is the single cause of the radial shift in HC innervation pattern observed in *ephrin-A5*<sup>-/-</sup> cochleae.


To test whether *EphA4* is the receptor through which *ephrin-A5* induces sorting of SGN projections, we used a mouse line encoding an *EphA4* forward signalling-deficient isoform<sup>26</sup>.

The proportion of fibres targeting the OHC layer was found to be significantly higher in *EphA4*<sup>EGFP/EGFP</sup> compared with WT animals both at P2 (Fig. 3f,g,m) and after hearing onset (Fig. 4a-j,q). Ribbon counts confirmed this radial shift from the IHC layer to the OHC layer in *EphA4*<sup>EGFP/EGFP</sup> mice (Fig. 4k-p), whereas both  $\beta$ III-tubulin<sup>+</sup> (type I and II) and peripherin<sup>+</sup> (type II) SGN survival remain unchanged (Supplementary Fig. S3g-l). In contrast, the percentage of type II fibres whose length is  $< 200 \mu\text{m}$  after entering the OC is, respectively, increased and decreased in *EphA4*<sup>EGFP/EGFP</sup> mice as compared with WT (Fig. 4g-j,r), suggesting a mechanism of axon competition. Mimicking the *ephrin-A5*<sup>-/-</sup> phenotype, these results therefore suggest that *EphA4* forward signalling is required for sorting of radial SGN projections.

**Ephrin-A5/*EphA4* induces type I SGN growth cone collapse.** To confirm the hypothesis that *EphA4* is required for type I axon repulsion upon binding to *ephrin-A5*, we performed




**Figure 3 | Ephrin-A5/EphA4 forward signalling is required for the sorting of radial SGN projections.** (a) Schematic representation of *in vivo* and *in vitro* protocols used to analyse cochlear innervation. (a) Type I and type II neurite extension to HCs (before birth), (b) neurite refinement and HC innervation (P0–P3) and (c) neurite retraction and synaptic pruning (P3–P6). WT and *ephrin-A5*<sup>-/-</sup> mice were killed at P2 (red cross). Explants of OC and SG from E18 embryos were treated *in vitro* with EphA7-Fc during 4 days (red bar). (b–g) Immunolabeling for NF-H alone or in combination with parvalbumin of whole-mount cochlea from P2 WT, *ephrin-A5*<sup>-/-</sup> and *EphA4*<sup>EGFP/EGFP</sup> mice. (b,d,f) In WT condition, most growth cones (arrowheads) stop beneath the first row of OHCs (dotted line). In *ephrin-A5*<sup>-/-</sup> (c,e) or *EphA4*<sup>EGFP/EGFP</sup> (g) mice, almost no collapsed growth cones can be observed, whereas many fibres aberrantly invade the OHC layer. (h–k) *In vitro* organotypic model using SG and OC cultured in the presence of control (IgG-Fc; h,j) or the soluble inhibitor EphA7-Fc (i,k) reagents. Double immunolabeling for βIII-tubulin and parvalbumin. (h,j) In the control condition, almost all afferent projections are retained to IHCs, and some stopping growth cones (arrowheads) can be observed at the limit between IHC and OHC layers (yellow dotted line). (i,k) When blocking endogenous ephrin-A5 signalling, a majority of fibres project to the OHC layer. (l,m) The proportion of fibres targeting the OHC region is significantly increased in *ephrin-A5*<sup>-/-</sup> (l) and *EphA4*<sup>EGFP/EGFP</sup> (m) versus WT mice (*n* = 3 animals for each genotype, \*\*\**P* < 0.01, \*\*\*\**P* < 0.001). (n) The proportion of afferent fibres targeting the OHC region is significantly increased in EphA7-Fc versus IgG-Fc condition (*n* = 3 independent experiments for both conditions; \*\**P* < 0.01). Statistical significance was determined using Student’s *t*-test. Data are presented as mean ± s.e.m. Scale bars in (b) and (h) represent 5 μm in (b–g) and (h–k), respectively.



growth cone collapse assays, in which dissociated SGNs from newborn mouse cochleae are exposed to pre-clustered ephrin-A5. After treatment, the majority of SGN neurites undergo growth cone collapse, as revealed by the F-actin marker phalloidin (Fig. 5b). The size reduction of growth cones (compare Fig. 5a,b) is correlated with phosphorylation of EphA4 on tyr-602 residue (Fig. 5b)<sup>27</sup>. By contrast, SGNs preferentially show large growth cones in the control condition, with no detectable EphA4 phospho-specific immunolabeling (Fig. 5a). Importantly, growth cones of peripherin<sup>+</sup> type II SGNs appear not sensitive to pre-clustered ephrin-A5, and remain similar to those found in the control condition (Fig. 5f). Quantitative analysis revealed that the proportion of type I growth cone collapse is significantly increased upon stimulation with ephrin-A5-Fc compared with the control condition (Fig. 5q). Such a result was confirmed using an *in vitro* stripe assay, in which a majority of SG

growth cones avoid the ephrin-A5-Fc-containing stripes (Supplementary Fig. 5). On the contrary, type I SGN growth cones from *EphA4*<sup>EGFP/EGFP</sup> mice, in which EGFP is expressed, do not collapse in the presence of ephrin-A5-Fc (Fig. 5g,q). These results therefore suggest that ephrin-A5 selectively induces growth cone collapse on type I SGNs through specific activation of EphA4.

We then tested whether the RhoA-associated kinase (ROCK)/myosin light chain kinase (MLCK) signalling pathway is involved in ephrin-A5-induced growth cone collapse, as previously shown in retinal ganglion cell<sup>28</sup> and hippocampal explant cultures<sup>29</sup>, respectively. Incubation of either p160 ROCK-specific inhibitor Y-27632 or MLCK inhibitor ML-7 in primary culture of SGNs result in a significant rescue of ephrin-A5-induced growth cone collapse (Fig. 5q). These results were confirmed in organotypic culture assay. Blocking either ROCK or MLCK results in a



**Figure 5 | Ephrin-A5 induces growth cone collapse on type I SGNs through activation of EphA4.** (a,b,f,g) Representative examples of *in vitro* growth cone collapse assay on dissociated SGNs from newborn mice using control IgG-Fc or pre-clustered ephrin-A5-Fc. (a) In the control condition, SGNs show a large growth cone with no sign of EphA4 phosphorylation. (b) Upon incubation with pre-clustered ephrin-A5-Fc, F-actin marker tetramethyl rhodamine isothiocyanate-phalloidin (red) reveals severe growth cone collapse simultaneously co-localized with EphA4 phospho-specific (tyr-602) immunolabeling. (f) Growth cones of type II SGNs (peripherin<sup>+</sup>, green) are not sensitive to clustered ephrin-A5, and their structure remains similar to those observed in the control condition. (g) Type I SGN growth cones from *EphA4<sup>EGFP/EGFP</sup>* mice, in which EGFP is expressed, do not collapse in the presence of ephrin-A5-Fc. (c-e,h-j) Signalling proteins downstream of EphA4 activation. Ephrin-A5-induced growth cone collapse coincides with phosphorylation of ephexin-1 (h), cofilin (i) and myosin light chain-2 (MLC-2) (j) compared with control condition (c,d,e). (k-p) *In vitro* organotypic model using SG and OC cultured in the presence of dimethylsulphoxide (k,n), Y-27632 (l,o) or ML-7 (m,p). (k,n) Under control conditions, almost all afferent fibres are retained to IHCs and some stopping fibres (arrowheads) can be observed at the limit between IHC and OHC layers (yellow dotted line). When blocking endogenous ROCK (l,o) or MLCK (m,p) signalling pathways, a majority of fibres project to the OHC layer. (q) The proportion of type I growth cone collapse is significantly increased upon stimulation with ephrin-A5-Fc compared with the control condition, but not when type I SGNs lack EphA4 forward signalling. This effect is significantly rescued by pre-treatment with either Y-27632 or ML-7. By contrast, the proportion of type II growth cone collapse is not increased upon stimulation with ephrin-A5-Fc compared with the control condition. *n* = 3 independent experiments for each condition. \*\**P* < 0.01, \*\*\**P* < 0.001. (r) The percentage of afferent fibres targeting the OHC layer is significantly increased in the presence of either Y-27632 or ML-7 inhibitors. *n* = 3 independent experiments for each condition. \*\**P* < 0.01 Statistical significance was determined using one-way ANOVA test followed by a Dunnett's post-test. Data are presented as mean ± s.e.m. Scale bars in (a) and (k) represent 5 μm in (a-j) and (k-p), respectively.

radial shift of afferent innervation pattern from IHC to OHC layers as compared with control (dimethylsulphoxide) condition (Fig. 5k-p,r), without affecting neuron survival (Supplementary Fig. S3o-r). In addition, we found that growth cone collapse coincides with phosphorylation of three potential downstream signalling proteins of EphA4: the guanine nucleotide exchange factor ephexin-1<sup>30</sup>, the actin-depolymerizing and -severing factor cofilin-1<sup>31</sup> and the ATP-dependent motor protein myosin-2 (responsible for actin-based motility)<sup>32</sup> (Fig. 5h,i,j, respectively).

These findings support a requirement of the RhoA-ROCK/cofilin/MLCK signalling pathway downstream of EphA4 receptor activation by ephrin-A5 (Fig. 7d).

**Ephrin-A5 is required for optimal IHC neurotransmission.** To assess the hearing function when *ephrin-A5* is missing, we performed auditory brainstem response (ABR) recordings on 3-month-old WT and *ephrin-A5*<sup>-/-</sup> mice, as we found that radial

shift in HC innervation pattern is conserved until adulthood (as shown in the apical turn, Supplementary Fig. S6). ABR measurements were obtained using click stimuli. Hearing thresholds remained similar for both genotypes (Fig. 6a). However, ABR amplitudes to suprathreshold click stimuli were altered in *ephrin-A5*<sup>-/-</sup> animals. In particular, ABR peak I amplitude reflecting the summed activity of cochlear afferents<sup>33,34</sup> is significantly decreased at several intensity levels and, on average, is 40% smaller in mice lacking *ephrin-A5* (Fig. 6b,c). This deficient neurotransmission probably arises from reduced number of IHC afferent connections by type I SGNs caused by partial mistargeting of type I projections to OHCs (Fig. 2 and Supplementary Fig. S6).

## Discussion


In the mid 1990s, it was suggested that brain-derived neurotrophic factor and neurotrophin-3 specifically support the innervation of OHCs and IHCs through activation of *trkB* or *trkC* receptors on type II and type I SGNs, respectively<sup>35</sup>. However, further studies revealed that, even if neurotrophins via *trk* receptors clearly promote SGN survival and fibre outgrowth during development, these molecules fail to explain by themselves the formation of proper afferent connections between HCs and SGNs<sup>36</sup>.

In this study, we provide a model describing how type I and type II SGNs specifically innervate IHCs and OHCs, respectively. This mechanism involves complementary and specific spatio-temporal expressions of *ephrin-A5* in OHCs and *EphA4* in type I SGNs throughout the perinatal period of axonal refinement leading to HC innervation (Fig. 1)<sup>5</sup>. Analysis of *ephrin-A5*<sup>-/-</sup> mice suggests that a subset of type I SGNs overshoot the IHCs and abnormally project into the OHC region, adopting consequently the behaviour of type II innervation (Fig. 7b). This phenotype was reproduced by *in vitro* organotypic assay when blocking *ephrin-A5*-binding ability with a soluble inhibitor (*EphA7-Fc*), arguing that type I SGNs express an appropriate *EphA/EphB2* receptor needed to specifically interact with *ephrin-A5*. Differentially expressed among SGN populations, *EphA4* was also found to be specifically activated through selective *ephrin-A5*-mediated type I growth cone collapse (Fig. 5). In addition, forward signalling-deficient *EphA4*<sup>EGFP/EGFP</sup> mice provide a radial shift in HC afferent innervation pattern comparable to the one observed in *ephrin-A5*<sup>-/-</sup> animals. Given the crucial involvement of *ephrin-A5/EphA4* interactions in establishing thalamocortical mapping<sup>13</sup>, we believe that, in the cochlea, the auditory innervation pattern is achieved on a similar


model. Indeed, we show that *EphA4*<sup>+</sup> type I SGNs connect *ephrin-A5*<sup>-</sup> IHCs, whereas despite the presence of repulsive cues in target cells *EphA4*<sup>-</sup> type II SGNs manage to project to *ephrin-A5*<sup>+</sup> OHCs (Fig. 7a and c). Thus, it is tempting to speculate that *EphA4* is the partner of *ephrin-A5* in this repulsive/permissive system. In contrast, *EphB2*, although known to interact with *ephrin-A5*<sup>16</sup>, does not seem to be a good candidate, as it is equally expressed in both type I and type II SGNs.

This model is compatible with recent data showing that, during the anterior stage of fibre outgrowth and extension to the OC, *EphA4* is expressed in the otic mesenchyme and interacts with *ephrin-B2* on developing SGN axons<sup>25</sup>. Indeed, it can be suggested that, at late embryonic stages, *EphA4* promotes SGN fasciculation through *ephrin-B2* reverse signalling; once afferents have reached the OC, *EphA4* (expressed in type I SGNs) forward signalling controls target specification through interaction with *ephrin-A5* (expressed by OHCs) at early postnatal stages. Importantly, this hypothesis of a double role for *EphA4* is supported by the fact that, in addition to be expressed in the otic mesenchyme, *EphA4* mRNA was also found in the SG<sup>25</sup>.

Perinatally, during HC innervation process, although type I fibres are specifically refined to basolateral regions of IHCs, some collateral branches (CBs) establish temporary synaptic contacts with OHCs that are pruned at later stages<sup>5,37,38</sup>. Importantly, numerous type I SGNs have both a main fibre refining to IHC and a CB forming a transient synapse with OHCs. How do these transient projections manage to reach *ephrin-A5*<sup>+</sup> target cells? We observed that, in addition to be expressed in OHCs, *ephrin-A5* seems to be dynamically expressed at perinatal stages in a subset of SGNs that do not belong to type II SGNs, therefore partially overlapping the expression of *EphA4* (Fig. 1o–u). Although we found that this *ephrin-A5*<sup>+</sup> SGN subpopulation reaches a peak at P0, knowing exactly whether this is a consistent subpopulation or whether type I SGNs are all expressing *ephrin-A5* but at different times remains to be determined. Depending on the local neural network to be formed, recent work has shown that coexpressed *Eph* and *ephrins* *cis*-interact and mutually inactivate each other in the same cell, thereby fine-tuning the sensitivity of navigating axons to *ephrins* from the target tissue presented in *trans*<sup>39–41</sup>. Furthermore, the relative contribution of *trans* signalling and *cis* attenuation is influenced by the subcellular distribution of both *ephrins* and *Ephs*<sup>39,42</sup>. Therefore, it can be hypothesized that, within a given type I SGN in which *EphA4* and *ephrin-A5* are coexpressed, the presence of *ephrin-A5* protein is exclusively confined to the CB, where it could mediate *cis* silencing of *EphA4* forward signalling, preventing growth cone collapse and enabling the successful



**Figure 6 | Ephrin-A5 is required for optimal neurotransmission from IHCs to the auditory nerve.** (a) Hearing thresholds are similar in both WT and *ephrin-A5*<sup>-/-</sup> mice. ABR measurements were established using click stimuli. (b) ABR waveforms from *ephrin-A5*<sup>-/-</sup> (grey) exhibit decreased peak I amplitude compared with WT (black) mice. Peak II is generated by the central portion of VIIIth cranial nerve; Peak III by the cochlear nucleus; Peak IV by the superior olivary complex/lateral lemniscus; Peak V by the lateral lemniscus/inferior colliculus. (c) Peak I amplitude is significantly reduced when using 30, 40, 50, 60 and 80 dB SPL stimulation and, on average, is 40% smaller in *ephrin-A5*<sup>-/-</sup> mice.  $n = 12$  animals for both genotypes. \* $P < 0.05$ , \*\* $P < 0.01$ . Statistical significance was determined using Student's *t*-test. Data are presented as mean  $\pm$  s.e.m.



**Figure 7 | Schematic model summarizing the contribution of ephrin-A5/EphA4 in afferent targeting to HCs in the OC.** (a,b) *Ephrin-A5* (blue) and *EphA4* (green) genes are expressed at perinatal stages in OHCs and type I SGNs, respectively. These complementary patterns match one another given the known SG to HCs topography, with type I SGNs connecting IHCs and type II SGNs (purple) widely projecting to OHCs (purple arrowheads in A). (a) In the WT condition, ephrin-A5 from OHCs provides a repulsive signal to EphA4<sup>+</sup> type I axons (green). (b) In the absence of *ephrin-A5*, a subset of type I SGNs send ectopic projections to the OHCs region, giving rise to incomplete type II innervation (purple arrowheads indicate the new early endpoints) compared with WT (purple arrowheads in A). (c,d) A model for how ephrin-A5/EphA4 interactions control specific SGN afferent targeting to corresponding HCs. (c) When EphA4<sup>+</sup> type I SGNs reach ephrin-A5<sup>-</sup> IHCs, ephexin-1 is stably bound to EphA4 at the membrane, where it contributes to activation of RhoA, among other GTPases. RhoA supports a basal level of actomyosin-based contractility resulting in a forward movement. (d) When EphA4<sup>+</sup> type I SGNs reach ephrin-A5<sup>+</sup> OHCs, EphA4 activation enhances ephexin-1 activity toward RhoA. ROCK activation inhibits both cofilin-mediated f-actin depolymerization and myosin light chain phosphatase activity, favouring the accumulation of f-actin stress fibres and phospho-myosin light chain-2. Both components synergistically increase the actomyosin-based contraction, leading to growth cone collapse, therefore preventing type I SGN from targeting the OHCs. In red, the elements that were experimentally tested. limK, lim kinase; mlc, myosin light chain; mlcp, mlc phosphatase; mlck, mlc kinase.

formation of transient type I—OHC synapses. By contrast, in the meantime, the main type I fibre would remain EphA4<sup>+</sup>/ephrin-A5<sup>-</sup>, involving the repulsion of type I fibre upon binding to ephrin-A5<sup>+</sup> OHCs and the subsequent refinement to IHCs (Supplementary Fig. 7).

In WT condition, type II afferents enter the OHC area relatively apically, turn to the base, arborize extensively and innervate tens of cells. Although previous work supports the fact that neurite growth of type II SGNs is highly directed towards OHCs<sup>43</sup>, the mechanisms (neurotrophic or intrinsic) that would underlie this process remain largely unclear. Here we found that the absence of either *ephrin-A5* or EphA4 forward signalling induces random invasion of the OHC layer by numerous ectopic fibres. Consequently, type II SGNs probably undergo axon competition and adapt by forming incomplete projections. This observation is consistent with the fact that competition for target territory refines the map by suppressing or eliminating branches<sup>44</sup>. Neuronal immunolabelings therefore reveal opposite shifts: a partial displacement of type I innervation from IHCs to OHCs and a subsequent withdrawal of type II projections from OHCs. This double defect is similar to what happens during retinocollicular map formation. Indeed, in the absence of ephrin-A5 anteroposterior gradient in the superior colliculus (SC) or EphA naso-temporal gradient in the retina, temporal axons (TAs) shift posteriorly. Nasal axons (NAs) therefore face increased competition in posterior SC, lose their affinity for this region and spread out anteriorly<sup>14,45</sup>. On the basis of gain- and loss-of-function analysis, a repulsion/competition model accounting for normal mapping has been proposed<sup>14,46</sup>. EphA<sup>+</sup> TAs are strongly repelled by posterior ephrins, and thus they terminate in the anterior SC. To avoid competition with TA in the anterior SC, EphA<sup>-</sup> NAs prefer to project only to the posterior SC. As similar defects were obtained in both situations using either *ephrin-A5*<sup>-/-</sup> mice or *in vivo* loss of EphA function, such a model could be transposed from retinocollicular mapping to auditory projections pattern in the cochlea. EphA4<sup>+</sup> type I fibres are repelled by ephrin-A5 from OHCs to IHCs. Founded on the observation that type II afferents fail to face strong type I axon competition in the OHC region, EphA4<sup>-</sup> type II afferents could not compete against multiple and dense type I connections at IHCs and prefer to project to OHCs. Such an explanation is not far from the idea that type I afferents may reach the OC earlier and occupy the available membrane surface on IHCs, thus leaving free synaptic space only on OHCs for type II fibers<sup>37</sup>. To precisely address this competition hypothesis, a mouse line devoid of type I SGNs should be created in order to observe whether, in the absence of competition, some type II SGNs connect the IHCs.

Electrophysiological measurements revealed that ephrin-A5 is dispensable for a normal hearing threshold. Given that type I afferents initially indifferently reach both types of HCs<sup>5</sup>, in the absence of *ephrin-A5*, a subset of type I projections should directly connect IHCs without interacting with OHCs. This residual type I innervation persisting at IHCs (Fig. 2) would therefore be sufficient to preserve a normal hearing threshold. However, an impaired neurotransmission from IHCs to the auditory nerve was recorded in *ephrin-A5*<sup>-/-</sup> animals and should result from the partial type I SGN mistargeting to OHCs, leading to the lack of IHC—type I afferent synapses. Interestingly, *EphA4*<sup>-/-</sup> mice show a similar decrease of ABR peak 1 amplitude<sup>47</sup>, reinforcing the hypothesis of a complementary contribution to ephrin-A5 in specific afferent targeting to HCs. Ribbon quantification revealed that radial shift of type I projections from IHCs to OHCs in both *ephrin-A5*<sup>-/-</sup> and *EphA4*<sup>EGFP/EGFP</sup> mice is accompanied by an increased number of presynaptic active zones in the OHC area (Figs 2 and 4). During the first postnatal week, type I SGNs extend transient collateral

projections to OHCs<sup>5</sup> and form synapses that express glutamate receptor subtypes<sup>48</sup> and trigger Ca<sup>2+</sup>- and otoferlin-dependent glutamate release, similar to what occurs in mature IHCs<sup>49</sup>. In adult cochlea, ribbons are believed to support afferent signalling from OHCs<sup>50</sup>. Concurrently, these findings suggest the idea that, in either *ephrin-A5*<sup>-/-</sup> or EphA4 forward signalling-deficient mice, some definitive type I—OHC ribbon-containing synapses could enhance the afferent neurotransmission from this region.

Altogether, our results indicate that, rather than occurring by any mechanisms of specific attraction as initially suggested<sup>35</sup>, the precise targeting of type I SGNs—IHCs versus type II SGNs—OHCs is dependent on ephrin-mediated mutual repulsion through matching complementary expression patterns of *ephrin* and *Eph* genes. This crucial finding could be usefully exploited in therapeutic strategies aimed at improving the neurotransmission from HCs to the cochlear nerve by selectively optimizing the afferent innervation of either IHCs or OHCs.

## Methods

**Animals.** WT and *ephrin-A5*<sup>-/-</sup>, *EphA4*<sup>+/EGFP</sup> and *EphA4*<sup>EGFP/EGFP</sup> littermates were obtained from heterozygous crosses, and the genotype was determined by PCR as previously described<sup>9,26</sup>. Mice were group-housed in the animal facility of the University of Liège under standard conditions with food and water *ad libitum* and were maintained on a 12-h light/dark cycle. All animals were taken care of in accordance with the declaration of Helsinki and following the guidelines of the Belgian ministry of agriculture in agreement with EC laboratory animal care and use regulation (86/609/CEE, CE of J n°L358, 18 December 1986).

**In vitro organotypic assay.** SG and OC were isolated together from E18 mouse cochlea and cultured in DMEM (Gibco) supplemented with glucose (final concentration 6 g l<sup>-1</sup>) and N1 additives (insulin (5 µg ml<sup>-1</sup>), transferrin (5 µg ml<sup>-1</sup>), putrescine (10<sup>-4</sup> M), progesterone (2 × 10<sup>-8</sup> M) and selenium ([Na<sub>2</sub>SeO<sub>3</sub>] 3 × 10<sup>-8</sup> M). Explants were treated with either IgG-Fc fragment as control or recombinant mouse EphA7-Fc chimera (5 µg ml<sup>-1</sup>; R&D Systems, Minneapolis, MN, USA), an ephrin-A5 inhibitor, during 4 days. Explants were also treated during the same time window with dimethylsulphoxide as control or Y-27632 dihydrochloride (10 µM; Tocris, Bristol, UK), a selective inhibitor of the RhoA-associated protein kinase p160ROCK and ML-7 (10 µM; Sigma-Aldrich, St Louis, MO, USA), a selective MLCK inhibitor.

**Primary culture of SGNs and growth cone collapse assay.** SGNs from newborn mice were isolated, cultured as previously described<sup>51</sup> and incubated with a 5 µg ml<sup>-1</sup> human ephrin-A5-Fc (R&D systems, Minneapolis, MN, USA) solution pre-clustered for 1 h at 37 °C with 50 µg ml<sup>-1</sup> anti-human IgG-Fc (R&D systems, Minneapolis, MN, USA). Before beginning growth cone collapse assay, cells were pre-treated with either Y-27632 dihydrochloride (7 h, 10 µM; Tocris, Bristol, UK) or ML-7 (5 h, 10 µM; Sigma-Aldrich, St Louis, MO, USA). After incubation with pre-clustered ephrin-A5 for 15 min in a humidified atmosphere of 5% CO<sub>2</sub>/95% air, SGNs were then fixed in 4% paraformaldehyde and immunolabeled using peripherin (rabbit polyclonal antibody, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), EphA4 (tyr-602) phospho-specific (rabbit polyclonal antibody, 1:100; ECM Biosciences, Versailles, KY, USA), green fluorescent protein (rat monoclonal IgG2a, 1:100; Gentaur, London, UK), ephexin-1 (tyr-87) phospho-specific (rabbit polyclonal antibody, 1:100; ECM Biosciences, Versailles, KY, USA), phospho-myosin light chain 2 (ser-19) (rabbit polyclonal antibody, 1:100; Cell Signaling, Danvers, MA, USA) or phospho-cofilin (ser-3) (rabbit monoclonal antibody, 1:100; Cell Signaling, Danvers, MA, USA) antibodies and tetramethyl rhodamine isothiocyanate-phalloidin (1:500; Sigma-Aldrich, St Louis, MO, USA) as an F-actin marker. The criteria for collapsed growth cones were a total loss of filopodia and lamellipodia and a strong decrease in F-actin content. Data were statistically analysed using one-way analysis of variance (ANOVA) followed by a Dunnett's post-test (GraphPad Prism software 4.0; GraphPad Software Inc., San Diego, CA, USA). *P*-values <0.05 were considered significant (\*\**P*<0.01).

**Tissue processing and immunostainings.** Embryo heads and postnatal cochlea were fixed for 2–24 h (time according to the sample size) in 4% paraformaldehyde and, if needed, decalcified for at least three days (0.1 M EDTA in PBS). Whole-mount cochlea, sections or explants were incubated overnight at 4 °C with primary antibodies directed against ephrin-A5 (goat IgG, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), green fluorescent protein (rat monoclonal IgG2a, 1:250; Gentaur, London, UK), peripherin (mouse monoclonal IgG1, 1:250; Acris Antibodies GmbH, Herford, Germany), βIII-tubulin (Tuj1) antibody, mouse monoclonal IgG2a, 1:2000; Covance Research Products, Princeton, NJ, USA), myosin-VII (rabbit IgG, 1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and parvalbumin (goat IgG, 1:5000; Swant, Marly, Switzerland), both specific

markers for HCs<sup>52,53</sup>, neurofilament H (rat IgG, clone TA51, 1:500; Millipore, Billerica, MA, USA) and CtBP2/RIBEYE (purified mouse IgG1, 1:250; BD Transduction Laboratories, Mississauga, ON, Canada). Tissues were then incubated for 1 h with either Rhodamine Red X-, fluorescein isothiocyanate- or Cy5-conjugated goat anti-mouse, anti-rabbit or anti-rat IgGs secondary antibodies (Jackson Immunoresearch Laboratories, Suffolk, UK).

For glutamate receptor subunit 2/3 (rabbit IgG, 1:200; Chemicon, Temecula, CA, USA)/CtBP2 double immunolabeling, freshly dissected apical cochlear turns were fixed with 99.9% ethanol (Merck, Darmstadt, Germany) for 20 min at  $-20^{\circ}\text{C}$ .

**Confocal microscopy, image analysis and quantifications.** Fluorescence pictures were acquired using the Olympus Fluoview FV1000 confocal system equipped with the Olympus IX81 inverted microscope (Olympus Europa GmbH, Germany) or the Leica SP2 confocal microscope (Leica, Wetzlar, Germany). Unless otherwise mentioned, fields were acquired using Z-scan, with a step of  $1\ \mu\text{m}$  between each confocal plane. For comparison between genotypes and culture conditions, all preparations were analysed at the same time, using the same acquisition parameters.

On whole-mount P2, 3-month and P14 cochleae, we considered, respectively, the proportion of NF-H<sup>+</sup> fibres beneath and beyond the row of IHCs and the number NF-H<sup>+</sup>/peripherin<sup>-</sup> fibres between IHC and OHC layers. Each explant was cut into three fragments consisting of apical, middle and basal turns of cochleae from WT, *ephrin-A5*<sup>-/-</sup> and *EphA4*<sup>EGFP/EGFP</sup> mice, and one corresponding region (as shown, for the apical turn, in Fig. 2a,b (magnifications)) measuring roughly  $200\ \mu\text{m}$  was considered for quantification. To avoid multiplication of graphs and statistics, in each case, data from individual turns were collapsed to give a single cochlea figure. At P2 and at 3 months, values were expressed as a percentage of fibres targeting the OHC layer. At P14, values were expressed as a mean axon number per  $100\ \mu\text{m}$  of cochlear length for each animal. Data were statistically analysed using a Student's *t*-test. *P*-values  $<0.05$  were considered significant (\*\**P* $<0.01$ ; \*\*\**P* $<0.001$ ). On whole-mount P14 cochleae, type II fibres were classified in two groups of length  $<200$  or  $>200\ \mu\text{m}$  after entering the OC. Measures were done using ImageJ software (NIH). Data were statistically analysed using Student's *t*-test. *P*-values  $<0.05$  were considered significant (\**P* $<0.05$ ; \*\**P* $<0.01$ ).

For each organotypic culture condition, we compared the number of  $\beta$ III-tubulin<sup>+</sup> fibres beneath and beyond the row of IHCs, and values were expressed as a percentage of fibres targeting the OHC layer. Depending on the number of conditions to be compared, data were statistically analysed using a Student's *t*-test or a one-way ANOVA test followed by a Dunnett's post-test. *P*-values  $<0.05$  were considered significant (\*\**P* $<0.01$ ; \*\*\**P* $<0.001$ ).

CtBP2<sup>+</sup> synaptic ribbons were quantified in about 12–15 IHCs and corresponding tangential OHCs in similar regions from apical, middle and basal turns of P14 cochleae from WT and *ephrin-A5*<sup>-/-</sup> or *EphA4*<sup>EGFP/EGFP</sup> mice. The number of ribbons was divided by the total number of IHC nuclei to obtain the number of synaptic ribbons/IHC or/row of OHCs (classically corresponding to three OHCs). In a subset of cochleae in which co-labelling for ribbons and postsynaptic AMPA receptors was performed, juxtaposed spots of ribbon and AMPA receptor immunofluorescence were counted and expressed as the number of synapses per IHC. Data were statistically analysed using a Student's *t*-test. *P*-values  $<0.05$  were considered significant (\**P* $<0.05$ ; \*\**P* $<0.01$ ; \*\*\**P* $<0.001$ ).

Total SGNs and type II SGNs from WT, *ephrin-A5*<sup>-/-</sup> or *EphA4*<sup>EGFP/EGFP</sup> P2 mice were quantified using a stereological reconstruction method<sup>54</sup>. Data were statistically analysed using a Student's *t*-test. In organotypic cultures, SGN population was quantified by considering three fields of SG per condition. Values were expressed as a mean number of SGNs per  $10000\ \mu\text{m}^2$ . Depending on the number of conditions to be compared, data were statistically analysed using a Student's *t*-test or a one-way ANOVA test. *Ephrin-A5*<sup>+</sup> and *EphA4*<sup>+</sup> SGNs were quantified at apical, middle and basal turns of E18–P6 cochleae after *in situ* hybridization (ISH) and  $\beta$ III-tubulin immunolabeling. Roughly 500 SGNs were quantified for each animal and for each probe. Data were expressed as a percentage of SGNs expressing *ephrin-A5* or *EphA4*.

**RNA ISH.** ISH was performed using digoxigenin-labelled *ephrin-A5* (ref. 55) and *EphA4* (ref. 56) riboprobes as previously described<sup>57</sup>. If needed, slides were classically immunolabeled with peripherin or  $\beta$ III-tubulin antibodies.

**In vitro stripe assay.** Stripe assay using recombinant control IgG-Fc or pre-clustered ephrin-A5-Fc was performed as previously described<sup>58</sup>. Ephrin-A5 stripes were labelled using anti-human IgG (Fc-specific)-Cy3-conjugated antibodies (1:100; Sigma-Aldrich, St. Louis, MO, USA). SGs from newborn mice were dissected and plated on stripes for 24–48 h. Neurons were then labelled using Calcein AM (1:1000; Invitrogen Molecular Probes, Eugene, OR, USA) for 1 h at  $37^{\circ}\text{C}$ , and pictures were acquired using the Olympus Fluoview FV1000 confocal system. Data were analysed by comparing the percentage of growth cones present in control IgG-Fc or ephrin-A5-Fc stripes using a Student's *t*-test. *P*-value  $<0.05$  was considered significant (\*\**P* $<0.01$ ).

**ABR recording.** Three-month-old mice were recorded as previously described<sup>59</sup>. ABR threshold was determined by detection of any wave in the complex. Data were

statistically analysed using a Student's *t*-test. *P*-values  $<0.05$  were considered significant (\**P* $<0.05$ ; \*\**P* $<0.01$ ).

## References

- Kiang, N. Y., Rho, J. M., Northrop, C. C., Liberman, M. C. & Ryugo, D. K. Hair-cell innervation by spiral ganglion cells in adult cats. *Science* **217**, 175–177 (1982).
- Spoendlin, H. Anatomy of cochlear innervation. *Am. J. Otolaryngol.* **6**, 453–467 (1985).
- Liberman, M. C. & Brown, M. C. Physiology and anatomy of single olivocochlear neurons in the cat. *Hear. Res.* **24**, 17–36 (1986).
- Strutz, J. Efferent innervation of the cochlea. *Ann. Otol. Rhinol. Laryngol.* **90**, 158–160 (1981).
- Huang, L. C., Thorne, P. R., Housley, G. D. & Montgomery, J. M. Spatiotemporal definition of neurite outgrowth, refinement and retraction in the developing mouse cochlea. *Development* **134**, 2925–2933 (2007).
- Defourny, J., Lallemand, F. & Malgrange, B. Structure and development of cochlear afferent innervation in mammals. *Am. J. Physiol. Cell Physiol.* **301**, C750–C761 (2011).
- Cheng, H. J., Nakamoto, M., Bergemann, A. D. & Flanagan, J. G. Complementary gradients in expression and binding of ELF-1 and Mek4 in development of the topographic retinotectal projection map. *Cell* **82**, 371–381 (1995).
- Flanagan, J. G. Neural map specification by gradients. *Curr. Opin. Neurobiol.* **16**, 59–66 (2006).
- Frisen, J. *et al.* Ephrin-A5 (AL-1/RAGS) is essential for proper retinal axon guidance and topographic mapping in the mammalian visual system. *Neuron* **20**, 235–243 (1998).
- Gale, N. W. *et al.* Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. *Neuron* **17**, 9–19 (1996).
- van Heumen, W. R., Claxton, C. & Pickles, J. O. Expression of EphA4 in developing inner ears of the mouse and guinea pig. *Hear. Res.* **139**, 42–50 (2000).
- Pickles, J. O., Claxton, C. & Van Heumen, W. R. Complementary and layered expression of Ephs and ephrins in developing mouse inner ear. *J. Comp. Neurol.* **449**, 207–216 (2002).
- Dufour, A. *et al.* Area specificity and topography of thalamocortical projections are controlled by ephrin/Eph genes. *Neuron* **39**, 453–465 (2003).
- Feldheim, D. A. *et al.* Genetic analysis of ephrin-A2 and ephrin-A5 shows their requirement in multiple aspects of retinocollicular mapping. *Neuron* **25**, 563–574 (2000).
- Hafidi, A. Peripherin-like immunoreactivity in type II spiral ganglion cell body and projections. *Brain Res.* **805**, 181–190 (1998).
- Himanen, J. P. *et al.* Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. *Nat. Neurosci.* **7**, 501–509 (2004).
- Ehret, G. Behavioural studies on auditory development in mammals in relation to higher nervous system functioning. *Acta Otolaryngol. Suppl.* **421**, 31–40 (1985).
- Fuchs, P. A., Glowatzki, E. & Moser, T. The afferent synapse of cochlear hair cells. *Curr. Opin. Neurobiol.* **13**, 452–458 (2003).
- Matthews, G. & Fuchs, P. The diverse roles of ribbon synapses in sensory neurotransmission. *Nat. Rev. Neurosci.* **11**, 812–822 (2010).
- Schmitz, F., Königstorfer, A. & Südhof, T. C. RIBEYE, a component of synaptic ribbons: a protein's journey through evolution provides insight into synaptic ribbon function. *Neuron* **28**, 857–872 (2000).
- Liberman, M. C., Dodds, L. W. & Pierce, S. Afferent and efferent innervation of the cat cochlea: quantitative analysis with light and electron microscopy. *J. Comp. Neurol.* **301**, 443–460 (1990).
- Kujawa, S. G. & Liberman, M. C. Adding insult to injury: cochlear nerve degeneration after 'temporary' noise-induced hearing loss. *J. Neurosci.* **29**, 14077–14085 (2009).
- Gao, P. P. *et al.* Regulation of thalamic neurite outgrowth by the Eph ligand ephrin-A5: implications in the development of thalamocortical projections. *Proc. Natl Acad. Sci. USA* **95**, 5329–5334 (1998).
- Brors, D. *et al.* EphA4 provides repulsive signals to developing cochlear ganglion neurites mediated through ephrin-B2 and -B3. *J. Comp. Neurol.* **462**, 90–100 (2003).
- Coate, T. M. *et al.* Otic mesenchyme cells regulate spiral ganglion axon fasciculation through a Pou3f4/EphA4 signaling pathway. *Neuron* **73**, 49–63 (2012).
- Grunwald, I. C. *et al.* Hippocampal plasticity requires postsynaptic ephrinBs. *Nat. Neurosci.* **7**, 33–40 (2004).
- Ellis, C. *et al.* A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. *Oncogene* **12**, 1727–1736 (1996).

28. Wahl, S., Barth, H., Ciossek, T., Aktories, K. & Mueller, B. K. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. *J. Cell. Biol.* **149**, 263–270 (2000).
29. Yue, X., Dreyfus, C., Kong, T. A. & Zhou, R. A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5. *Dev. Neurobiol.* **68**, 1269–1286 (2008).
30. Sahin, M. *et al.* Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse. *Neuron* **46**, 191–204 (2005).
31. Zhou, L. *et al.* EphA4 signaling regulates phospholipase Cgamma1 activation, cofilin membrane association, and dendritic spine morphology. *J. Neurosci.* **27**, 5127–5138 (2007).
32. Parri, M. *et al.* EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to rho-dependent actino/myosin contractility. *J. Biol. Chem.* **282**, 19619–19628 (2007).
33. Melcher, J. R. & Kiang, N. Y. Generators of the brainstem auditory evoked potential in cat. III: Identified cell populations. *Hear. Res.* **93**, 52–71 (1996).
34. Charizopoulou, N. *et al.* Gipc3 mutations associated with audiogenic seizures and sensorineural hearing loss in mouse and human. *Nat. Commun.* **2**, 201 (2011).
35. Ernborn, P., Van De Water, T., Loring, J. & Jaenisch, R. Complementary roles of BDNF and NT-3 in vestibular and auditory development. *Neuron* **14**, 1153–1164 (1995).
36. Fritsch, B., Tessarollo, L., Coppola, E. & Reichardt, L. F. Neurotrophins in the ear: their roles in sensory neuron survival and fiber guidance. *Prog. Brain. Res.* **146**, 265–278 (2004).
37. Echter, S. M. Developmental segregation in the afferent projections to mammalian auditory hair cells. *Proc. Natl Acad. Sci. USA* **89**, 6324–6327 (1992).
38. Simmons, D. D. A transient afferent innervation of outer hair cells in the postnatal cochlea. *Neuroreport* **5**, 1309–1312 (1994).
39. Kao, T. J. & Kania, A. Ephrin-mediated cis-attenuation of Eph receptor signaling is essential for spinal motor axon guidance. *Neuron* **71**, 76–91 (2011).
40. Carvalho, R. F. *et al.* Silencing of EphA3 through a cis interaction with ephrinA5. *Nat. Neurosci.* **9**, 322–330 (2006).
41. Dudanova, I. & Klein, R. The axon's balancing act: cis- and trans-interactions between Ephs and ephrins. *Neuron* **71**, 1–3 (2011).
42. Marquardt, T. *et al.* Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. *Cell* **121**, 127–139 (2005).
43. Koundakjian, E. J., Appler, J. L. & Goodrich, L. V. Auditory neurons make stereotyped wiring decisions before maturation of their targets. *J. Neurosci.* **27**, 14078–14088 (2007).
44. Ruthazer, E. S. & Cline, H. T. Insights into activity-dependent map formation from the retinotectal system: a middle-of-the-brain perspective. *J. Neurobiol.* **59**, 134–146 (2004).
45. Feldheim, D. A. *et al.* Loss-of-function analysis of EphA receptors in retinotectal mapping. *J. Neurosci.* **24**, 2542–2550 (2004).
46. Triplett, J. W. *et al.* Competition is a driving force in topographic mapping. *Proc. Natl Acad. Sci. USA* **108**, 19060–19065 (2011).
47. Miko, I. J., Henkemeyer, M. & Cramer, K. S. Auditory brainstem responses are impaired in EphA4 and ephrin-B2 deficient mice. *Hear. Res.* **235**, 39–46 (2008).
48. Knipper, M. *et al.* Transient expression of NMDA receptors during rearrangement of AMPA-receptor expressing fibers in the developing inner ear. *Cell Tissue Res.* **287**, 23–41 (1997).
49. Beurg, M. *et al.* Calcium- and otoferlin dependent exocytosis by immature outer hair cells. *J. Neurosci.* **28**, 1798–1803 (2008).
50. Knirsch, M. *et al.* Persistence of Ca(v)1.3 Ca<sup>2+</sup> channels in mature outer hair cells supports outer hair cell afferent signaling. *J. Neurosci.* **27**, 6442–6451 (2007).
51. Lallemand, F. *et al.* New insights into peripherin expression in cochlear neurons. *Neuroscience* **150**, 212–222 (2007).
52. Hasson, T., Heintzelman, M. B., Santos-Sacchi, J., Corey, D. P. & Mooseker, M. S. Expression in cochlea and retina of myosin VIIa, the gene product defective in Usher syndrome type 1B. *Proc. Natl Acad. Sci. USA* **92**, 9815–9819 (1995).
53. Yang, D., Thalmann, I., Thalmann, R. & Simmons, D. D. Expression of alpha and beta parvalbumin is differentially regulated in the rat organ of corti during development. *J. Neurobiol.* **58**, 479–492 (2004).
54. Richter, C. P., Kumar, G., Webster, E., Banas, S. K. & Whitlon, D. S. Unbiased counting of neurons in the cochlea of developing gerbils. *Hear. Res.* **278**, 43–51 (2011).
55. Flenniken, A. M., Gale, N. W., Yancopoulos, G. D. & Wilkinson, D. G. Distinct and overlapping expression patterns of ligands for Eph-related receptor tyrosine kinases during mouse embryogenesis. *Dev. Biol.* **179**, 382–401 (1996).
56. Nieto, M. A., Gilardi-Hebenstreit, P., Charnay, P. & Wilkinson, D. G. A receptor protein tyrosine kinase implicated in the segmental patterning of the hindbrain and mesoderm. *Development* **116**, 1137–1150 (1992).
57. Tiveron, M. C., Hirsch, M. R. & Brunet, J. F. The expression pattern of the transcription factor Phox2 delineates synaptic pathways of the autonomic nervous system. *J. Neurosci.* **16**, 7649–7660 (1996).
58. Knöll, B., Weinl, C., Nordheim, A. & Bonhoeffer, F. Stripe assay to examine axonal guidance and cell migration. *Nat. Protoc.* **2**, 1216–1224 (2007).
59. Buran, B. N. *et al.* Onset coding is degraded in auditory nerve fibres from mutant mice lacking synaptic ribbons. *J. Neurosci.* **30**, 7587–7597 (2010).

### Acknowledgements

We thank A. Brose, P. Ernst-Gengoux, P. -B. Van Lerberghe and N. Caron for their technical assistance. This work was supported by the Belgian Fonds National de la Recherche Scientifique (FNRS), and the Fonds Léon Fredericq (FLF, Faculty of Medicine-University of Liège). We thank Professor D. G. Wilkinson (Division of Developmental Neurobiology, Medical Research Council National Institute for Medical Research, London, UK) for providing both ephrin-A5 and EphA4 RNA probes, and Professor B. Knöll (Interfaculty Institute for Cell Biology, Department of Molecular Biology, University of Tübingen, Germany) for providing silicon matrices to produce stripe assay. We thank the GIGA-Cell Imaging platform. J.D. was supported by the Fonds pour la formation à la Recherche dans l'Industrie et l'Agriculture (FRIA) and FLF. F.L. is supported by the Swedish Research Council and Tysta Skolan. L.N. is funded by the Walloon excellence in lifesciences and biotechnology (WELBIO). L.N. and B.M. are, respectively, research associate and research director from FNRS. Work by J.N. and T.M. was supported by the German Research Foundation (through the Collaborative Research Centre 889).

### Author contributions

J.D. and B.M. designed research; J.D., S.M.S., J.N. and A.-L.P. performed research; T.M., E.S., K.K., C.P., B.F., L.N. and P.V. contributed new reagents/analytic tools; L.N., T.M., G.M. and B.M. gave conceptual advice on the project; J.D. wrote the paper; F.L., L.N. and B.M. discussed and revised the manuscript.

### Additional information

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Defourny, J. *et al.* Ephrin-A5/EphA4 signalling controls specific afferent targeting to cochlear hair cells. *Nat. Commun.* **4**:1438 doi: 10.1038/ncomms2445 (2013).